Business Standard

Dr Reddy's Lab rises 2.3%

Related News

The stock jumped 2.3 per cent to Rs 1,204.55 after the company said Phase-III clinical trial for its anti-diabetic molecule balaglitazone achieved the set parameters.

The company which conducted the study to determine the efficacy and safety of the drug, with Rheoscience — a subsidiary of said, it met its primary endpoint of reducing HbA1c or Glycoslated haemoglobin molecule, which indicates glucose level in blood. Besides, the oral anti-diabetic drug also showed effective results on fasting plasma glucose, oedeman and weight gain & body composition.

Read more on:   
|

Dr Reddy's Lab rises 2.3%

The stock jumped 2.3 per cent to Rs 1,204.55 after the company said Phase-III clinical trial for its anti-diabetic molecule balaglitazone achieved the set parameters.

The stock jumped 2.3 per cent to Rs 1,204.55 after the company said Phase-III clinical trial for its anti-diabetic molecule balaglitazone achieved the set parameters.

The company which conducted the study to determine the efficacy and safety of the drug, with Rheoscience — a subsidiary of said, it met its primary endpoint of reducing HbA1c or Glycoslated haemoglobin molecule, which indicates glucose level in blood. Besides, the oral anti-diabetic drug also showed effective results on fasting plasma glucose, oedeman and weight gain & body composition.

image

Recommended for you

Advertisements

Quick Links

Market News

Mentha oil down by 0.7% on subdued spot demand

Participants trimmed positions, tracking sluggish demand in the spot market

Chana gains by 0.3% on rising demand

Lower output estimates also fueled the uptrend

Crude palm oil slip by 0.2% on profit booking

Speculators booked profits at prevailing high levels coupled with fall in spot demand

Cardamom up by 0.4% as demand picks up

Tight supplies from producing belts also helped prices

Markets at day's high; Sensex soars 300 points, Nifty reclaims 8,400

At 11:06, the Sensex was trading higher by 302 points at 27,808 mark and the Nifty gained 94 points at 8,414

 

Back to Top